UTHR | tickerfilter.com

Fundamental analysis

58%

Profitability 57%

Dept financing 8%

Liquidity 75%

Performance 68%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.21%

1 Month

-3.64%

3 Months

-20.31%

6 Months

-15.80%

1 Year

24.67%

2 Year

27.97%

Key data

Stock price

$297.04

P/E Ratio

13.18

DAY RANGE

$293.70 - $298.68

EPS

$16.10

52 WEEK RANGE

$236.65 - $417.82

52 WEEK CHANGE

$26.76

MARKET CAP

15.752 B

YIELD

N/A

SHARES OUTSTANDING

44.491 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-30-2025

BETA

0.66

PUBLIC FLOAT

AVERAGE 10 VOLUME

$308,912

AVERAGE 30 VOLUME

$455,647

Company detail

CEO: Martine A. Rothblatt
Region: US
Website: unither.com
Employees: 980
IPO year: 1999

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise. Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD)

UTHR - UNITED THERAPEUTICS Corp